| |
Dual ART Therapy Regimens
|
| |
| |
Non-inferiority of dual-therapy with darunavir/ritonavir plus 3TC vs. triple therapy with darunavir/ritonavir plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014-RIS-EST45 Trial - DUAL: "DarUnavir And Lamivudine" - (11/09/16)
In naives at EACS 2015: Dual therapy with Lopinavir/ Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Naïve HIV-1 infected subjects : 48-week results of the GARDEL Study. (10/28/15)
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
CROI: Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17)
future prospect: Antiviral Activity of EFdA [MK-8591] Against NRTI-Sensitive and -Resistant Strains of HIV-2 - (02/24/17)
MK-8591 Concentrations at Sites of HIV Transmission and Replication - (02/23/17)
Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naïve patients 48 Week Results of the PADDLE trial. - (07/29/16) 2 phase 3 trials are ongoing looking at this
- GEMINI 1 & GEMINI 2. There is also this study, switching after viral suppression for patients With Intolerance or Toxicity to Nucleoside Analogues:
https://aidsinfo.nih.gov/clinical-trials/details/NCT02491242 - there will be a study switching from a TAF triple therapy called the TANGO Study.
Promising Results of Lamivudine + Dolutegravir Maintenance Therapy in ANRS 167 Lamidol Trial - (02/23/17)
Simplification to Atazanavir/Ritonavir + Lamivudine versus Maintaining Atazanavir/Ritonavir + 2NRTIs in Virologically Suppressed HIV-infected Patients: 48-weeks Data of the ATLAS-M Trial (10/26/15) published Jan 2017
Download the PDF here
Pdf attached above
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. published in 2015
Download the PDF here
Pdf attached above
Kaletra + 3TC, Maintenance - Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. published in 2015.
32 HIV units in hospitals in Spain and France. HIV-infected adults with HIV-1 RNA of less than 50 copies per mL, for at least 6 months on triple treatment with lopinavir-ritonavir (twice daily) plus lamivudine or emtricitabine and a second nucleos(t)ide, with no resistance or virological failure to these drugs, and no positive hepatitis B serum surface antigen. Investigators at each centre randomly assigned patients (1:1; block size of four; stratified by time to suppression [<1 year or >1 year] and nadir CD4 cell count [<100 cells per μL or >100 cells per μL]. Findings: Between Oct 1, 2011, and April 1, 2013, we randomly assigned 250 participants to continue triple treatment (127 [51%] patients) or switch to dual treatment (123 [49%] patients). In the intention-to-treat population, 110 (86⋅6%) of 127 patients in the triple-treatment group responded to treatment versus 108 (87⋅8%) of 123 in the dual-treatment group (difference -1⋅2% [95% CI -9⋅6 to 7⋅3]; p=0⋅92), meeting the criteria for non-inferiority. Serious adverse events occurred in eight (7%) patients in the triple-treatment group and five (4%) in the dual-treatment group (p=0⋅515), and study drug discontinuations due to adverse events occurred in four (3%) in the triple-treatment group and one (1%) in the dual-treatment group (p=0⋅223). Interpretation: Dual treatment with lopinavir-ritonavir plus lamivudine has non-inferior therapeutic efficacy and is similarly tolerated to triple treatment.
Download the PDF here
Pdf attached above
|
|
| |
| |
|
|
|
